KNEE OA TRIAL ENROLLS FIRST SUBJECT (Orthopedics This Week)
San Diego-based Cytori Therapeutics, Inc. has treated its first patient in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee. Peter Hanson, M.D., medical director of Orthopedic Surgery at Sharp Grossmont Hospital, took care of the patient.
The trial, called ACT-OA, is a Phase II FDA randomized, double-blind placebo controlled trial involving 90 patients. They will be evaluated on the efficacy and safety of Cytori’s autologous adipose derived therapy called ECCO-50. The trial will test bo...
The Orthopedics Industry 
